SCHEMBL7940896

SCHEMBL7940896

CN(F)[C@@](F)(CCCN)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ODC1 P11926 2/20 0.44
LMNA P02545 3/20 0.42
BLM P54132 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
PMP22 Q01453 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
CHRM5 P08912 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
THRB P10828 2/20 0.32
KMT2A Q03164 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
GABRR3 A8MPY1 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
HDAC3 O15379 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29001334 0.83 ODC1 (0.43) ODC1LMNABLMKDM4EMAPT
SCHEMBL6151309 0.82 ODC1 (0.41) ODC1LMNABLMKDM4EMAPT
SCHEMBL6151308 0.82 ODC1 (0.41) ODC1LMNABLMKDM4EMAPT
SCHEMBL5069038 0.81 CHRM2 (0.40) ODC1LMNABLMKDM4EMAPT
SCHEMBL30116554 0.79 ODC1 (0.50) ODC1LMNABLMKDM4EMAPT
SCHEMBL1249526 0.79 ODC1 (0.40) ODC1LMNABLMKDM4EMAPT
SCHEMBL15909004 0.72 CES2 (0.38) KMT2ACYP1A2MEN1
SCHEMBL15909003 0.72 CES2 (0.38) KMT2ACYP1A2MEN1
SCHEMBL28113559 0.70 ODC1 (0.54) ODC1LMNABLMKDM4EMAPT
Trifluoroacetic Acid SCHEMBL31080805 0.69 ODC1 (0.48) ODC1LMNABLMKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4448556-A1 CELL PENETRATING POLYPEPTIDES (CPPS) AND THEIR USE IN HUMAN THERAPY RDP Pharma AG (CH) 2024-10-23 EP disclosed
WO-2023111213-A1 CELL PENETRATING POLYPEPTIDES (CPPS) AND THEIR USE IN HUMAN THERAPY RDP PHARMA AG (CH) 2023-06-22 WO disclosed
EP-1067919-A1 DFMO AND SULINDAC COMBINATION IN CANCER CHEMOPREVENTION THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA (US) 2001-01-17 EP disclosed
WO-1999049859-A9 DFMO AND SULINDAC COMBINATION IN CANCER CHEMOPREVENTION UNIV ARIZONA (US) 1999-11-25 WO disclosed
WO-1999049859-A1 DFMO AND SULINDAC COMBINATION IN CANCER CHEMOPREVENTION THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 1999-10-07 WO disclosed